Toll-like receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
=== Physical properties === Plutonium, like most metals, has a bright silvery appearance at first, much like nickel, but it oxidizes very quickly to a dull gray, though yellow and olive green are also reported. At room temperature plutonium is in its α (alpha) form. This allotrope is about as hard and brittle as gray cast iron. When plutonium is alloyed with other metals, the high-temperature δ allotrope is stabilized at room temperature, making it soft and ductile. Unlike most metals, it is not a good conductor of heat or electricity. It has a low melting point (640 °C, 1,184 °F) and an unusually high boiling point (3,228 °C, 5,842 °F). This gives a large range of temperatures (over 2,500 kelvin wide) at which plutonium is liquid, but this range is neither the greatest among all actinides nor among all metals, with neptunium theorized to have the greatest range in both instances. The low melting point as well as the reactivity of the native metal compared to the oxide leads to plutonium oxides being a preferred form for applications such as nuclear fission reactor fuel (MOX-fuel). Alpha decay, the release of a high-energy helium nucleus, is the most common form of radioactive decay for plutonium. A 5 kg mass of 239Pu contains about 12.5×1024 atoms. With a half-life of 24,100 years, about 11.5×1012 of its atoms decay each second by emitting a 5.157 MeV alpha particle. This amounts to 9.68 watts of power. Heat produced by the deceleration of these alpha particles makes it warm to the touch.
In the large intestine the passage of the digesting food in the colon is a lot slower, taking from 30 to 40 hours until it is removed by defecation. The colon mainly serves as a site for the fermentation of digestible matter by the gut flora. The time taken varies considerably between individuals. The remaining semi-solid waste is termed feces and is removed by the coordinated contractions of the intestinal walls, termed peristalsis, which propels the excreta forward to reach the rectum and exit through the anus via defecation. The wall has an outer layer of longitudinal muscles, the taeniae coli, and an inner layer of circular muscles. The circular muscle keeps the material moving forward and also prevents any back flow of waste. Also of help in the action of peristalsis is the basal electrical rhythm that determines the frequency of contractions. The taeniae coli can be seen and are responsible for the bulges (haustra) present in the colon. Most parts of the GI tract are covered with serous membranes and have a mesentery. Other more muscular parts are lined with adventitia.
== Military career == Wilson served with the Rhodesian African Rifles (RAR) before passing selection for the Rhodesian Special Air Service (SAS) in July 1975. He commanded B Squadron from January 1976–February 1978 and was promoted to become second-in-command of the regiment from March 1978–May 1980. He took command in 1980. Wilson's first decoration for valour was the BCR which was awarded on 07 Oct 1977 while he was still a Captain. His second, the SCR, was awarded on 13 April 1979 with Major Wilson in the 2IC post. Following Rhodesia's reconstitution and recognised independence as Zimbabwe in 1980, Wilson was awarded the Grand Cross of Valour on 30 June 1980 while a Major and second-in-command. He was the second and final person to be awarded the honour after Chris Schulenburg, who received the award while serving with the Selous Scouts. Wilson was awarded Wings on Chest (WOC) on 18 April 1979. During Rhodesia's transition to Zimbabwe, Wilson obtained the rank of major and retired after serving as Officer Commanding SAS from April 1980 to the unit's disbandment in December that year. He delivered the final regimental address at Kabrit Barracks on 13 December 1980, before the final lowering of the colours. An account of the role of the SAS in the Rhodesian Bush War was authored by Wilson and Greg Mills, entitled Who Dares Loses: Assessing Rhodesia's Counter-Insurgency Experience. Wilson was appointed as the President of the C-Squadron Rhodesian Special Air Service Association following the death of General Peter Walls.
=== Abnormal folate metabolism === Several lines of evidence indicate abnormalities of folate metabolism in ASD. These abnormalities can lead to a decrease in 5-methyltetrahydrofolate production, alter the production of folate metabolites and reduce folate transport across the blood-brain barrier and in neurons. The most significant abnormalities of folate metabolism associated with ASD may be autoantibodies to the alpha folate receptor (FRα). These autoantibodies have been associated with cerebral folate deficiency. Autoantibodies can bind to FRα and greatly impair its function. In 2013, one study reported that 60% and 44% of 93 children with ASD were positive for FRα-blocking and binding autoantibodies, respectively. This high rate of anti-FRα autoantibody positivity was confirmed by Ramaekers et al. who compared 75 children with ASD to 30 non-autistic "controls". These controls were children who had a developmental delay, but did not have ASD. FRα-blocking autoantibodies were positive in 47% of children with ASD, but only in 3% of children without ASD. The authors of this study (RE Frye, JM Sequeira, EV Quadros, SJ James and DA Rossignol) have contributed to other such studies on FRα autoantibodies with similar results, however are considered to have a conflict of interest by the publishers. Many children with ASD and cerebral folate deficiency have marked improvements in their clinical status when taking folinic acid.
In the early 1930s, William Astbury showed that there were drastic changes in the X-ray fiber diffraction of moist wool or hair fibers upon significant stretching. The data suggested that the unstretched fibers had a coiled molecular structure with a characteristic repeat of ≈5.1 ångströms (0.51 nanometres). Astbury initially proposed a linked-chain structure for the fibers. He later joined other researchers (notably the American chemist Maurice Huggins) in proposing that:
Sources: en.wikipedia.org
Studies concluded that the tone of media coverage of Sanders was more favorable than that of any other candidate, whereas his main opponent in the Democratic primary, Hillary Clinton, received the most negative coverage of any candidate. All 2016 candidates received vastly less media coverage than Donald Trump, and the Democratic primary received substantially less coverage than the Republican primary. Amy Goodman of Democracy Now! noted that on March 15, Super Tuesday III, the speeches of Trump, Clinton, Marco Rubio, and Ted Cruz were broadcast in full. Sanders was in Phoenix, Arizona, on that date, speaking to a rally larger than any of the others, yet his speech was not mentioned, let alone broadcast. However, political scientist Rachel Bitecofer wrote in her 2018 book about the 2016 election that the Democratic primary was effectively over in terms of delegate count by mid-March 2016, but that the media promoted the narrative that the contest between Sanders and Clinton was "heating up" at that time. An NBC/Wall Street Journal poll conducted in May 2016 found Clinton and Trump (by then the presumptive Republican nominee) in a "dead heat", but the same poll found that if Sanders were the Democratic nominee, 53% of voters would support him to 39% for Trump. Clinton and Trump were the least popular likely candidates ever polled, while Sanders received a 43% positive, 36% negative rating. Polls showed that Democratic voters older than 50 preferred Clinton by a large margin but that those under 50 overwhelmingly favored Sanders.
=== Food additive === As a food additive, ammonium sulfate is considered generally recognized as safe (GRAS) by the U.S. Food and Drug Administration, and in the European Union it is designated by the E number E517. It is used as an yeast nutrient in breads.
The first documented use of electrical stimulation for pain relief dates back to 46 AD when Scribonius Largus of the ancient Roman Empire used the electric properties of torpedo fish to relieve headaches. Scientific studies of neuromodulation began in 1745, when German physician De Haen published "a number of cases of spasmodic, paralytic and other nervous affections cured by electricity". The first implementation of electrocutical apparatus in hospital medical treatment recorded in Middlesex Hospital of London in 1767. In 1780, Italian physicist and biologist Luigi Galvani investigated how electrical signals in nerves could control muscle movement, further evidence of the electrical nature of the neuronal activity.
Present data show that (R)-phenylpiracetam increases motivation, i.e., the work load, which animals are willing to perform to obtain more rewarding food. At the same time consumption of freely available normal food does not increase. Generally this indicates that (R)-phenylpiracetam increase motivation [...] The effect of (R)-phenylpiracetam is much stronger than that of methylphenidate and amphetamine.
== Mechanism of action == Unlike many other psychoactive drugs, lithium typically produces no obvious psychotropic effects (such as euphoria) in normal individuals at therapeutic concentrations. The specific biochemical mechanism of lithium action in stabilizing mood is unknown. However, it is known that lithium works at the level of G-proteins, PIP2, and other second messengers. Lithium carbonate is a white, odorless, alkaline powder. Upon ingestion, lithium becomes widely distributed in the central nervous system and interacts with a number of neurotransmitters and receptors, decreasing norepinephrine release and increasing serotonin synthesis by neurons in the brain. In vitro studies performed on serotonergic neurons from rat raphe nuclei have shown that when these neurons are treated with lithium, serotonin release is enhanced during a depolarization compared to no lithium treatment and the same depolarization. Lithium has a plethora of proposed molecular targets:
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.